Generic Name and Formulations:
Cycloserine 250mg; caps.
Lilly, Eli and Company
Indications for SEROMYCIN:
In conjunction with other chemotherapy, for the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible and when treatment with primary drugs (streptomycin, isoniazid, rifampin, ethambutol) has proved inadequate.
Initially 250mg twice daily at 12-hour intervals for the first 2 weeks. Usual dose: 500mg–1g daily in divided doses monitored by blood levels. Max 1g/day.
Epilepsy. Depression. Severe anxiety. Psychosis. Severe renal insufficiency. Excessive concurrent use of alcohol.
Discontinue or reduce dose if allergic dermatitis or CNS toxicity develops. Ratio of toxic dose to effective dose is small. Monitor blood levels, hematologic, renal, and liver function. Obtain weekly blood levels in patients with reduced renal function, patients receiving >500mg daily dosage, or those showing signs/symptoms suggestive of toxicity. Pregnancy (Cat.C). Nursing mothers: not recommended.
Neurotoxic effects with concomitant ethionamide. Increased risk of epileptic episodes with alcohol. Increased CNS effects with concomitant isoniazid; monitor closely.
CNS effects (eg, convulsions, drowsiness, somnolence, headache, tremor, dysarthria, vertigo, confusion, psychoses, character changes, hyperirritability, aggression, paresis, hyperreflexia, paresthesia, seizures, coma), CHF, allergy, rash, elevated serum transaminase (esp. with preexisting liver disease), anemia (monitor).
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency